Critical review of the role of HTS in drug discovery

Drug Discovery Today

Volumn 11, Issue 7-8, 2006, Pages 277-279

  Macarron, Ricardo ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ENZYME; G PROTEIN COUPLED RECEPTOR; IMATINIB; ION CHANNEL; PHOSPHOTRANSFERASE;

COMBINATORIAL CHEMISTRY; DRUG INDUSTRY; DRUG SCREENING; DRUG TARGETING; EDITORIAL; GENOMICS; HIGH THROUGHPUT SCREENING; LABORATORY TEST;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 33645887230     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.02.001     Document Type: Editorial

References (19)

1. Eggeling C., et al. Highly sensitive fluorescence detection technology currently available for HTS. Drug Discov. Today 8 (2003) 632-641
2. Haber C., et al. Precise nanoliter fluid handling system with integrated high-speed flow sensor. Assay Drug Dev. Technol. 3 (2005) 203-212
3. Davis A.M., et al. Components of successful lead generation. Curr. Top. Med. Chem. 5 (2005) 421-439
4. Landers P. Human element: drug industry's big push into technology falls short - testing machines were built to streamline research but may be stifling it - officials see payoff after 2010. The Wall Street Journal (2004) Feb 24
5. Spencer R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol. Bioeng. 61 (1998) 61-67
6. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
7. Gribbon P., and Sewing A. High-throughput drug discovery: what can we expect from HTS?. Drug Discov. Today 10 (2005) 17-22
8. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
9. Sittampalam G.S., et al. Design of signal windows in high throughput screening assays for drug discovery. J. Biomol. Screen 2 (1997) 159-169
10. Taylor P.B., et al. A standard operating procedure for assessing liquid handler performance in high-throughput screening. J. Biomol. Screen 7 (2002) 554-569
11. Moore S.D. Bacteria resistant to antibiotics have reason to worry - SmithKline scraps traditional lab, uses gene research to create nnovative drug. The Wall Street Journal (1995) Oct 20
12. Fishman M.C., and Porter J.A. Pharmaceuticals - a new grammar for drug discovery. Nature 437 (2005) 491-493
13. DiMasi J.A., et al. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
14. Fox S., et al. High throughput screening 2002: moving toward increased success rates. J. Biomol. Screen 7 (2002) 313-316
15. Fox S., et al. High-throughput screening: searching for higher productivity. J. Biomol. Screen 9 (2004) 354-358
16. von Ahsen O., and Bomer U. High-throughput screening for kinase inhibitors. ChemBioChem 6 (2005) 481-490
17. Valler M.J., and Green D. Diversity screening versus focused screening in drug discovery. Drug Discov. Today 5 (2000) 286-293
18. Butler M.S. The role of natural product chemistry in drug discovery. J. Nat. Prod. 67 (2004) 2141-2153
19. Chan P.F., et al. Novel antibacterials: a genomics approach to drug discovery. Curr. Drug Targets Infect. Disord. 2 (2002) 291-308